[Cytogenetic response as a marker of efficacy of chronic myeloid leukemia therapy with a BCR-ABL thyrosine kinase inhibitor glivek].
Turkina AG, Kruglov SS, Druzhkova GA, Domracheva EV, Zakharova AV, Vinogradova OIu, Sysoeva EP, Diachenko LV, Chelysheva EIu, Zakharova ES, Abakumov EM, Kolosheĭnova TI, Kolosova LIu, Ivanova TV, Zhuravlev VS, Nemchenko IS, Zingerman BV, Kurova ES, Triputen' NZ, Loriia SS, Kovaleva LG, Khoroshko ND.
Turkina AG, et al. Among authors: sysoeva ep.
Ter Arkh. 2005;77(7):42-7.
Ter Arkh. 2005.
PMID: 16116908
Russian.